Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.

Pediatric pulmonology - 1 May 2022

Kramer-Golinkoff Emily, Camacho Amanda, Kramer Liza, Taylor-Cousar Jennifer L

Abstract excerpt

BACKGROUND: While the advent of cystic fibrosis transmembrane conductance regulator (CFTR) modulator use has improved daily life and long-term prognosis of CF for many with approved CFTR mutations, approximately 10% of people with CF (pwCF) have only symptomatic treatments available. METHODS: Between June 10 and July 1, 2021, Emily's Entourage distributed a 38-question anonymous survey targeted at pwCF not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cystic Fibrosis
Share to Cystic Fibrosis Transmembrane Conductance Regulator

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Surveys and Questionnaires

Source

Open in PubMed Open full text

Identifiers

PMID: 35170259
DOI: 10.1002/ppul.25859
PMCID: PMC9314897

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators.PMID 35170259Read ↗

Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.Semantic proximity Read ↗

Delivering a New Future for People With Cystic Fibrosis.Semantic proximity Read ↗

Standards for the care of people with cystic fibrosis; establishing and maintaining health.Semantic proximity Read ↗

Review of CFTR modulators 2020.Semantic proximity Read ↗

The ageing of people living with cystic fibrosis: what to expect now?Semantic proximity Read ↗

Use of CFTR modulators in special populations, part 2: Severe lung disease.Semantic proximity Read ↗

Beyond the Lungs-Emerging Challenges in Adult Cystic Fibrosis Care.Semantic proximity Read ↗

Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.Semantic proximity Read ↗

Disease burden in people with cystic fibrosis heterozygous for F508del and a minimal function mutation.Semantic proximity Read ↗

Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study.Semantic proximity Read ↗

Patients with cystic fibrosis who could not receive the CFTR modulator treatment: What did they lose in 1 year?Semantic proximity Read ↗

Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.